Black Diamond Therapeutics Inc banner

Black Diamond Therapeutics Inc
NASDAQ:BDTX

Watchlist Manager
Black Diamond Therapeutics Inc Logo
Black Diamond Therapeutics Inc
NASDAQ:BDTX
Watchlist
Price: 2.39 USD 2.58% Market Closed
Market Cap: $136.2m

Multiples-Based Value

The Multiples-Based Value of one BDTX stock under the Base Case scenario is hidden USD. Compared to the current market price of 2.39 USD, Black Diamond Therapeutics Inc is hidden .

Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

BDTX Multiples-Based Value
LOCKED
Unlock
Worst Case
Base Case
Best Case

Multiples Across Competitors

BDTX Competitors Multiples
Black Diamond Therapeutics Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Black Diamond Therapeutics Inc
NASDAQ:BDTX
136.6m USD 2 6.1 0.3 0.4
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 690 872.8 -160 127.7 -194 446.1 -192 227.3
US
Abbvie Inc
NYSE:ABBV
369.2B USD 6 88.2 14.6 20.3
US
Amgen Inc
NASDAQ:AMGN
187.5B USD 5.1 24.3 14.1 14.1
US
Gilead Sciences Inc
NASDAQ:GILD
174.1B USD 5.9 20.4 12.7 15.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
113.6B USD 9.3 28.2 21.2 22.1
US
Epizyme Inc
F:EPE
94.1B EUR 2 091 -533.6 -581 -565.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
80.5B USD 5.6 17.9 13.3 15.2
AU
CSL Ltd
ASX:CSL
68.5B AUD 3.1 34 11.3 14.2
NL
argenx SE
XBRU:ARGX
39.6B EUR 11.3 36.2 39.3 40.1
US
Seagen Inc
F:SGT
39.3B EUR 20.1 -61.8 -66.6 -60.1
P/S Multiple
Revenue Growth P/S to Growth
US
Black Diamond Therapeutics Inc
NASDAQ:BDTX
Average P/S: 3 063 002.9
2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
33 690 872.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
5.1
3%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
5.9
5%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.3
11%
0.8
US
E
Epizyme Inc
F:EPE
2 091
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.6
10%
0.6
AU
CSL Ltd
ASX:CSL
3.1
4%
0.8
NL
argenx SE
XBRU:ARGX
11.3
27%
0.4
US
S
Seagen Inc
F:SGT
20.1
30%
0.7
P/E Multiple
Earnings Growth PEG
US
Black Diamond Therapeutics Inc
NASDAQ:BDTX
Average P/E: 31.9
6.1
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 127.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
88.2
97%
0.9
US
Amgen Inc
NASDAQ:AMGN
24.3
20%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
20.4
16%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
28.2
17%
1.7
US
E
Epizyme Inc
F:EPE
Negative Multiple: -533.6 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.9
13%
1.4
AU
CSL Ltd
ASX:CSL
34
10%
3.4
NL
argenx SE
XBRU:ARGX
36.2
32%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.8 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Black Diamond Therapeutics Inc
NASDAQ:BDTX
Average EV/EBITDA: 15.9
0.3
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 446.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
14.6
12%
1.2
US
Amgen Inc
NASDAQ:AMGN
14.1
10%
1.4
US
Gilead Sciences Inc
NASDAQ:GILD
12.7
9%
1.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
21.2
16%
1.3
US
E
Epizyme Inc
F:EPE
Negative Multiple: -581 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.3
18%
0.7
AU
CSL Ltd
ASX:CSL
11.3
7%
1.6
NL
argenx SE
XBRU:ARGX
39.3
50%
0.8
US
S
Seagen Inc
F:SGT
Negative Multiple: -66.6 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Black Diamond Therapeutics Inc
NASDAQ:BDTX
Average EV/EBIT: 17.8
0.4
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 227.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
20.3
23%
0.9
US
Amgen Inc
NASDAQ:AMGN
14.1
3%
4.7
US
Gilead Sciences Inc
NASDAQ:GILD
15.7
13%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.1
17%
1.3
US
E
Epizyme Inc
F:EPE
Negative Multiple: -565.5 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.2
23%
0.7
AU
CSL Ltd
ASX:CSL
14.2
10%
1.4
NL
argenx SE
XBRU:ARGX
40.1
51%
0.8
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.1 N/A N/A
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett